Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access
Journal of Health Care for the Poor and Underserved · 2026-11 · 37 (4) · 1446-1450
DOI: 10.1353/hpu.2026.a1005877 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Health Care for the Poor and Underserved, 2026-11. Verfasst von Yara E Tovar und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Tirzepatide, Medicaid, Health Services Accessibility, Diabetes Mellitus, Type 2.
Abstract (Originalsprache)
Medicaid beneficiaries often face barriers to accessing evidence-based metabolic therapies, even as U.S. Food and Drug Administration (FDA) indications for agents such as tirzepatide expand. Although tirzepatide is approved for type 2 diabetes (T2D), obstructive sleep apnea (OSA), and obesity, some state Medicaid programs apply diagnosis-based restrictions that do not align with FDA labeling or clinical practice. We describe a 34-year-old woman with obesity, T2D, and OSA who experienced repeated denials for tirzepatide under Ohio Medicaid, despite meeting FDA-approved criteria for multiple indications. Diagnostic silos, contradictory exclusion rules, and inconsistent authorization pathways delayed treatment for six months, requiring multiple appeals, peer-to-peer reviews, and a state hearing before approval. This case illustrates how rigid coverage criteria can override clinical judgment and impede timely treatment. Variation across Medicaid programs limits access to glucagon-like peptide-1 (GLP-1)–based therapies. Aligning coverage with FDA labeling is essential to ensuring equitable, patient-centered care for underserved populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Tovar, Y. E., & Jun, J. Y. (2026). Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access. Journal of Health Care for the Poor and Underserved, 37(4), 1446-1450. https://doi.org/10.1353/hpu.2026.a1005877
Vancouver
Tovar YE, Jun JY. Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access. Journal of Health Care for the Poor and Underserved. 2026;37(4):1446-1450. doi:10.1353/hpu.2026.a1005877
BibTeX
@article{Tovar2026,
author = {Tovar, Yara E and Jun, John Y},
title = {Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access},
journal = {Journal of Health Care for the Poor and Underserved},
year = {2026},
volume = {37},
number = {4},
pages = {1446--1450},
doi = {10.1353/hpu.2026.a1005877}
}
EUVIMED